Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer

Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

(2016) Xiaoxian (Bill) Li et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer

(2016) Xiaoxian Li et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas

(2016) Drew G. Davis et al.   HUMAN PATHOLOGY

Clinical implications of molecular heterogeneity in triple negative breast cancer

(2015) Brian D. Lehmann et al.   BREAST

Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer

(2015) Elizabeth A. Mittendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer

(2014) Jung Eun Choi et al.   ANNALS OF SURGICAL ONCOLOGY

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

(2014) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network

(2012) Nancy U. Lin et al.   CANCER

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention: Time to Modify the Current American Joint Committee on Cancer Staging System

(2011) Min Yi et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-Negative Breast Cancer

(2010) Ayca Gucalp et al.   CANCER JOURNAL

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

(2009) Tomasz Byrski et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

(2009) C. J. Creighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute